Dovato is a prescription medication used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents who have no known history of prior antiviral treatment for HIV-1 [1]. It is a complete, single-tablet regimen that combines two antiretroviral drugs: dolutegravir and lamivudine [1].
What is Dovato's active ingredient and how does it work?
Dovato contains two active ingredients: dolutegravir and lamivudine. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that works by blocking the integrase enzyme, which HIV needs to replicate. Lamivudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) that also interferes with HIV replication by inhibiting the reverse transcriptase enzyme [1].
How is Dovato administered and what is the typical dosage?
Dovato is an oral medication taken as a single tablet once a day [1]. The standard dosage is one tablet containing 65 mg of dolutegravir and 50 mg of lamivudine [1].
What are the potential side effects of Dovato?
Common side effects associated with Dovato may include diarrhea, nausea, headache, fatigue, and dizziness [1]. Serious side effects can occur, such as hypersensitivity reactions, liver problems, and lactic acidosis [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Who should not take Dovato?
Dovato is contraindicated in patients with known hypersensitivity to dolutegravir or lamivudine, or to any of its ingredients [1]. It should also not be used in patients with severe renal impairment (creatinine clearance less than 30 mL per minute) or in patients who are taking dofetilide [1].
How does Dovato compare to other HIV treatment options?
Dovato is a single-tablet regimen, which can simplify treatment adherence compared to multi-pill regimens. It is indicated for treatment-naive individuals, meaning those who have not previously taken antiretroviral therapy for HIV-1 [1]. The choice of HIV medication is individualized based on factors such as viral load, CD4 count, potential drug interactions, and patient history [2].
What is the patent status and exclusivity period for Dovato?
Information regarding the specific patent expiration dates and market exclusivity for Dovato can be found on DrugPatentWatch.com [3]. These details are crucial for understanding when generic versions of the medication may become available.
Where can I find more information on Dovato and HIV treatment?
Further detailed prescribing information, including warnings, precautions, and clinical trial data for Dovato, is available from the manufacturer and through resources like the U.S. National Library of Medicine's DailyMed [1]. DrugPatentWatch.com offers comprehensive patent and exclusivity information for pharmaceutical products [3]. For general information on HIV/AIDS, the Centers for Disease Control and Prevention (CDC) is a key resource [2].
Sources
1. Dovato Prescribing Information
2. Centers for Disease Control and Prevention (CDC) HIV/AIDS
3. DrugPatentWatch.com